CEFPODOXIME PROXETIL - cefpodoxime proxetil granule, for suspension Aurobindo Pharma Limited

Cefpodoxime Proxetil for Oral Suspension, USP

Rx only


To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

For Oral Use Only

DESCRIPTION

Cefpodoxime proxetil is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. The chemical name is (RS)-1(isopropoxycarbonyloxy) ethyl (+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl)-2-{(Z)methoxyimino}acetamido]-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-ene- 2-carboxylate.

Its molecular formula is $C_{21}H_{27}N_5O_9S_2$ and its structural formula is represented below:



The molecular weight of cefpodoxime proxetil is 557.6.

Cefpodoxime proxetil is a prodrug; its active metabolite is cefpodoxime. All doses of cefpodoxime proxetil in this insert are expressed in terms of the active cefpodoxime moiety. The drug is supplied as flavoured granules for oral suspension.

Each 5 mL of cefpodoxime proxetil for oral suspension USP contains cefpodoxime proxetil USP equivalent to 50 mg or 100 mg of cefpodoxime activity after constitution and the following inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, ferric oxide yellow, hydroxypropyl cellulose, microcrystalline cellulose and carboxymethyl cellulose sodium, colloidal silicon dioxide, citric acid anhydrous, sodium citrate, sodium benzoate, sucrose, and citron & vanille flavorings.

CLINICAL PHARMACOLOGY

Absorption and Excretion:

Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically. Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours. There is minimal metabolism of cefpodoxime *in vivo*.

Effects of Food:

When a 200 mg dose of the suspension was taken with food, the extent of absorption (mean AUC) and mean peak plasma concentration in fed subjects were not significantly different from fasted subjects, but the rate of absorption was slower with food (48% increase in T_{max}).

Pharmacokinetics of Cefpodoxime Proxetil Suspension:

In adult subjects, a 100 mg dose of oral suspension produced an average peak cefpodoxime concentration of approximately 1.5 mcg/mL (range: 1.1 to 2.1 mcg/mL), which is equivalent to that reported following administration of the 100 mg tablet. Time to peak plasma concentration and area under the plasma concentration-time curve (AUC) for the oral suspension were also equivalent to those produced with film-coated tablets in adults following a 100 mg oral dose.

The pharmacokinetics of cefpodoxime were investigated in 29 patients aged 1 to 17 years. Each patient received a single, oral, 5 mg/kg dose of cefpodoxime oral suspension. Plasma and urine samples were collected for 12 hours after dosing. The plasma levels reported from this study are as follows:

CEFPODOXIME PLASMA LEVELS (mcg/mL) IN FASTED PATIENTS (1 to 17 YEARS OF AGE) AFTER SUSPENSION ADMINISTRATION

Dose	Time after oral ingestion						
(cefpodoxime equivalents)	1hr	2hr	3hr	4hr	6hr	8hr	12hr
5 mg/kg^1	1.4	2.1	2.1	1.7	0.9	0.4	0.09

¹ Dose did not exceed 200 mg.

Distribution:

Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.

Skin Blister:

Following multiple-dose administration every 12 hours for 5 days of 200 mg or 400 mg cefpodoxime proxetil, the mean maximum cefpodoxime concentration in skin blister fluid averaged 1.6 and 2.8 mcg/mL, respectively. Skin blister fluid cefpodoxime levels at 12 hours after dosing averaged 0.2 and 0.4 mcg/mL for the 200 mg and 400 mg multiple-dose regimens, respectively.

Tonsil Tissue:

Following a single, oral 100 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in tonsil tissue averaged 0.24 mcg/g at 4 hours post-dosing and 0.09 mcg/g at 7 hours post-dosing. Equilibrium was achieved between plasma and tonsil tissue within 4 hours of

dosing. No detection of cefpodoxime in tonsillar tissue was reported 12 hours after dosing. These results demonstrated that concentrations of cefpodoxime exceeded the MIC₉₀ of *S. pyogenes* for at least 7 hours after dosing of 100 mg of cefpodoxime proxetil.

Lung Tissue:

Following a single, oral 200 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in lung tissue averaged 0.63 mcg/g at 3 hours post-dosing, 0.52 mcg/g at 6 hours post-dosing, and 0.19 mcg/g at 12 hours post-dosing. The results of this study indicated that cefpodoxime penetrated into lung tissue and produced sustained drug concentrations for at least 12 hours after dosing at levels that exceeded the MIC_{90} for *S. pneumoniae* and *H. influenzae*.

CSF:

Adequate data on CSF levels of cefpodoxime are not available.

Effects of Decreased Renal Function:

Elimination of cefpodoxime is reduced in patients with moderate to severe renal impairment (<50 mL/min creatinine clearance). (See **PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**.) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours. In subjects with moderate (30 to 49 mL/min creatinine clearance) or severe renal impairment (5 to 29 mL/min creatinine clearance), the half-life increased to 5.9 and 9.8 hours, respectively. Approximately 23% of the administered dose was cleared from the body during a standard 3-hour hemodialysis procedure.

Effect of Hepatic Impairment (cirrhosis):

Absorption was somewhat diminished and elimination unchanged in patients with cirrhosis. The mean cefpodoxime $T_{1/2}$ and renal clearance in cirrhotic patients were similar to those derived in studies of healthy subjects. Ascites did not appear to affect values in cirrhotic subjects. No dosage adjustment is recommended in this patient population.

Pharmacokinetics in Elderly Subjects:

Elderly subjects do not require dosage adjustments unless they have diminished renal function. (See **PRECAUTIONS**.) In healthy geriatric subjects, cefpodoxime half-life in plasma averaged 4.2 hours (Vs 3.3 in younger subjects) and urinary recovery averaged 21% after a 400 mg dose was administered every 12 hours. Other pharmacokinetic parameters (C_{max} , AUC, and T_{max}) were unchanged relative to those observed in healthy young subjects.

Microbiology:

Mechanism of Action:

Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.

Mechanism of Resistance:

Resistance to Cefpodoxime is primarily through hydrolysis by beta-lactamase, alteration of penicillinbinding proteins (PBPs), and decreased permeability.

Cefpodoxime has been shown to be active against most isolates of the following bacteria, both *in vitro* and in clinical infections as described in the Indications and Usage (1) section:

Gram-positive bacteria:

Staphylococcus aureus (methicillin-susceptible strains, including those producing penicillinases) Staphylococcus saprophyticus Streptococcus pneumoniae (excluding penicillin-resistant isolates) Streptococcus pyogenes

Gram-negative bacteria:

Escherichia coli Klebsiella pneumoniae Proteus mirabilis Haemophilus influenzae (including beta-lactamase producing isolates) Moraxella catarrhalis Neisseria gonorrhoeae (including penicillinase-producing isolates)

The following *in vitro* data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an *in vitro* minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for Cefpodoxime. However, the efficacy of Cefpodoxime in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.

Gram-positive bacteria:

Streptococcus agalactiae Streptococcus spp. (Groups C, F, G) **Gram-negative bacteria:** Citrobacter diversus Klebsiella oxytoca Proteus vulgaris

Providencia rettgeri

Haemophilus parainfluenzae

Anaerobic Gram-positive bacteria:

Peptostreptococcus magnus

Susceptibility Testing:

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

INDICATIONS AND USAGE

Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.

Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by *Streptococcus pneumoniae* (excluding penicillin-resistant strains), *Streptococcus pyogenes, Haemophilus influenzae* (including beta-lactamase-producing strains), or *Moraxella (Branhamella) catarrhalis* (including beta-lactamase producing strains).

Pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes*.

NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available.

Community-acquired pneumonia caused by *S. pneumoniae* or *H. Influenzae* (including beta-lactamase-producing strains).

Acute bacterial exacerbation of chronic bronchitis caused by *S. pneumoniae*, *H. influenzae* (non-beta-lactamase-producing strains only), or *M. catarrhalis*. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of *H. influenzae*.

Acute, uncomplicated urethral and cervical gonorrhea caused by *Neisseria gonorrhoeae* (including penicillinase-producing strains).

Acute, uncomplicated ano-rectal infections in women due to *Neisseria gonorrhoeae* (including penicillinase-producing strains).

NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by *N*. *gonorrhoeae* has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to *N*. *gonorrhoeae* in men or women.

Uncomplicated skin and skin structure infections caused by *Staphylococcus aureus* (including penicillinase-producing strains) or *Streptococcus pyogenes*. Abscesses should be surgically drained as clinically indicated.

NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications. (See **DOSAGE AND ADMINISTRATION**.)

Acute maxillary sinusitis caused by *Haemophilus influenzae* (including beta-lactamase-producing strains), *Streptococcus pneumoniae*, and *Moraxella catarrhalis*.

Uncomplicated urinary tract infections (cystitis) caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, or *Staphylococcus saprophyticus*.

NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil's lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (See **CLINICAL STUDIES** section.)

Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

Cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.

WARNINGS

BEFORE THERAPY WITH CEFPODOXIME PROXETIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFPODOXIME, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFPODOXIME PROXETIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefpodoxime proxetil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

A concerted effort to monitor for *C. difficile* in cefpodoxime-treated patients with diarrhea was undertaken because of an increased incidence of diarrhea associated with *C. difficile* in early trials in normal subjects. *C. difficile* organisms or toxin was reported in 10% of the cefpodoxime-treated adult patients with diarrhea; however, no specific diagnosis of pseudomembranous colitis was made in these patients.

In post-marketing experience outside the United States, reports of pseudomembranous colitis associated with the use of cefpodoxime proxetil have been received.

PRECAUTIONS

General:

In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of cefpodoxime proxetil should be reduced because high and prolonged serum antibiotic concentrations can occur in such individuals following usual doses. Cefpodoxime, like other cephalosporins, should be administered with caution to patients receiving concurrent treatment with potent diuretics. (See **DOSAGE AND ADMINISTRATION**.)

As with other antibiotics, prolonged use of cefpodoxime proxetil may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken. Prescribing cefpodoxime proxetil in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients:

Patients should be counseled that antibacterial drugs including cefpodoxime proxetil should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefpodoxime proxetil is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefpodoxime proxetil or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Drug Interactions:

Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H_2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in T_{max}), but do not affect the extent of absorption (AUC).

Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.

Nephrotoxic drugs: Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.

Drug/Laboratory Test Interactions:

Cephalosporins, including cefpodoxime proxetil, are known to occasionally induce a positive direct Coombs' test.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term animal carcinogenesis studies of cefpodoxime proxetil have not been performed. Mutagenesis studies of cefpodoxime, including the Ames test both with and without metabolic activation, the chromosome aberration test, the unscheduled DNA synthesis assay, mitotic recombination and gene conversion, the forward gene mutation assay and the *in vivo* micronucleus test, were all negative. No untoward effects on fertility or reproduction were noted when 100 mg/kg/day or less (2 times the human dose based on mg/m²) was administered orally to rats.

Pregnancy

Teratogenic Effects:

Pregnancy Category B

Cefpodoxime proxetil was neither teratogenic nor embryocidal when administered to rats during

organogenesis at doses up to 100 mg/kg/day (2 times the human dose based on mg/m²) or to rabbits at doses up to 30 mg/kg/day (1 to 2 times the human dose based on mg/m²).

There are, however, no adequate and well-controlled studies of cefpodoxime proxetil use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery:

Cefpodoxime proxetil has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.

Nursing Mothers:

Cefpodoxime is excreted in human milk. In a study of 3 lactating women, levels of cefpodoxime in human milk were 0%, 2% and 6% of concomitant serum levels at 4 hours following a 200 mg oral dose of cefpodoxime proxetil. At 6 hours post-dosing, levels were 0%, 9% and 16% of concomitant serum levels. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use:

Safety and efficacy in infants less than 2 months of age have not been established.

Geriatric Use:

Of the 3338 patients in multiple-dose clinical studies of cefpodoxime proxetil film-coated tablets, 521 (16%) were 65 and over, while 214 (6%) were 75 and over. No overall differences in effectiveness or safety were observed between the elderly and younger patients. In healthy geriatric subjects with normal renal function, cefpodoxime half-life in plasma averaged 4.2 hours and urinary recovery averaged 21% after a 400 mg dose was given every 12 hours for 15 days. Other pharmacokinetic parameters were unchanged relative to those observed in healthy younger subjects.

Dose adjustment in elderly patients with normal renal function is not necessary.

ADVERSE REACTIONS

Clinical Trials:

In clinical trials using multiple doses of cefpodoxime proxetil granules for oral suspension, 2128 pediatric patients (93% of whom were less than 12 years of age) were treated with the recommended dosages of cefpodoxime (10 mg/kg/day Q 24 hours or divided Q 12 hours to a maximum equivalent adult dose).

There were no deaths or permanent disabilities in any of the patients in these studies. Twenty-four patients (1.1%) discontinued medication due to adverse events thought possibly or probably related to study drug. Primarily, these discontinuations were for gastrointestinal disturbances, usually diarrhea, vomiting, or rashes.

Adverse events thought possibly or probably related, or of unknown relationship to cefpodoxime proxetil for oral suspension in multiple dose clinical trials (N=2128 patients treated with cefpodoxime) were:

Incidence Greater Than 1%:

Diarrhea

The incidence of diarrhea in infants and toddlers (age 1 month to 2 years) was 12.8%.

Diaper rash/Fungal skin rash 2% (includes moniliasis)

The incidence of diaper rash in infants and toddlers was 8.5%.

Other skin rashes	1.8%
Vomiting	2.3%

Incidence Less Than 1%:

Body: Localized abdominal pain, abdominal cramp, headache, monilia, generalized abdominal pain, asthenia, fever, fungal infection.

Digestive: Nausea, monilia, anorexia, dry mouth, stomatitis, pseudomembranous colitis.

Hemic & Lymphatic: Thrombocythemia, positive direct Coombs' test, eosinophilia, leukocytosis, leukopenia, prolonged partial thromboplastin time, thrombocytopenic purpura.

Metabolic & Nutritional: Increased SGPT.

Musculo-Skeletal: Myalgia.

Nervous: Hallucination, hyperkinesia, nervousness, somnolence.

Respiratory: Epistaxis, rhinitis.

Skin: Skin moniliasis, urticaria, fungal dermatitis, acne, exfoliative dermatitis, maculopapular rash.

Special Senses: Taste perversion.

Laboratory Changes

Significant laboratory changes that have been reported in adult and pediatric patients in clinical trials of cefpodoxime proxetil, without regard to drug relationship, were:

Hepatic: Transient increases in AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, bilirubin, and LDH.

Hematologic: Eosinophilia, leukocytosis, lymphocytosis, granulocytosis, basophilia, monocytosis, thrombocytosis, decreased hemoglobin, decreased hematocrit, leukopenia, neutropenia, lymphocytopenia, thrombocytopenia, thrombocythemia, positive Coombs' test, and prolonged PT, and PTT.

Serum Chemistry: Hyperglycemia, hypoglycemia, hypoalbuminemia, hypoproteinemia, hyperkalemia, and hyponatremia.

Renal: Increases in BUN and creatinine.

Most of these abnormalities were transient and not clinically significant.

Post-marketing Experience:

The following serious adverse experiences have been reported: allergic reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and serum sickness-like reactions, pseudomembranous colitis, bloody diarrhea with abdominal pain, ulcerative colitis, rectorrhagia with hypotension, anaphylactic shock, acute liver injury, *in utero* exposure with miscarriage, purpuric nephritis, pulmonary infiltrate with eosinophilia, and eyelid dermatitis. One death was attributed to pseudomembranous colitis and disseminated intravascular coagulation.

Cephalosporin Class Labeling:

In addition to the adverse reactions listed above which have been observed in patients treated with cefpodoxime proxetil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics:

Adverse Reactions and Abnormal Laboratory Tests: Renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, serum sickness-like reaction, hemorrhage, agranulocytosis, and pancytopenia.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. (See **DOSAGE AND ADMINISTRATION** and **OVERDOSAGE**.) If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

OVERDOSAGE

In acute rodent toxicity studies, a single 5 g/kg oral dose produced no adverse effects.

In the event of serious toxic reaction from overdosage, hemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised.

The toxic symptoms following an overdose of beta-lactam antibiotics may include nausea, vomiting, epigastric distress, and diarrhea.

DOSAGE AND ADMINISTRATION

(See INDICATIONS AND USAGE for indicated pathogens.)

Cefpodoxime proxetil for oral suspension may be given without regard to food. The recommended dosages, durations of treatment, and applicable patient populations are as described in the following chart:

Type of Infection	Total Daily Dose	Dose Frequency	Duration
Pharyngitis and/or tonsillitis	200 mg	100 mg Q 12 hours	5 to 10 days
Acute community-	400 mg	200 mg Q 12 hours	14 days
acquired pneumonia	_	-	_
Uncomplicated gonorrhea (men	200 mg	single dose	
and women) and		-	
rectal gonococcal			
infections (women)			
Skin and skin structure	800 mg	400 mg Q 12 hours	7 to 14 days
Acute maxillary sinusitis	400 mg	200 mg Q 12 hours	10 days
Uncomplicated urinary tract	200 mg	100 mg Q 12 hours	7 days
infection	C .		

Adults and Adolescents (age 12 years and older):

Type of Infection	Total Daily Dose	Dose Frequency	Duration
Acute otitis media	10 mg/kg/day	5 mg/kg Q 12 h	5 days
	(Max 400 mg/day)	(Max 200 mg/dose)	
Pharyngitis and/or tonsillitis	10 mg/kg/day	5 mg/kg/dose Q 12 h	5 to 10 days
	(Max 200 mg/day)	(Max 100 mg/dose)	
Acute maxillary sinusitis	10 mg/kg/day	5 mg/kg Q 12 hours	10 days
	(Max 400 mg/day)	(Max 200 mg/dose)	

Patients with Renal Dysfunction:

For patients with severe renal impairment (<30 mL/min creatinine clearance), the dosing intervals should be increased to Q 24 hours. In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.

When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to estimate creatinine clearance (mL/min). For this estimate to be valid, the serum creatinine level should represent a steady state of renal function.

Males:	<u>Weight (kg) x (140 - age)</u>
(mL/min)	72 x serum creatinine (mg/100 mL)
Females: (mL/min)	0.85 x above value

Patients with Cirrhosis:

Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) are similar to those in healthy subjects. Dose adjustment is not necessary in this population.

Directions for use:

Before reconstitution, remove the desiccant capsule by pulling out two small rings, then discard.

Preparation of Suspension:

Constitution Directions For Oral Suspension				
Constituted	Final	Directions		
Volume	Concentration			
50 mL	50 mg per 5 mL	Suspend in a total of 31 mL of distilled water. Method: First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, shaking vigorously after each aliquot of water.		
75 mL	50 mg per 5 mL	Suspend in a total of 44 mL of distilled water. Method: First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, shaking vigorously after each aliquot of water.		
100 mL	50 mg per 5 mL	Suspend in a total of 57 mL of distilled water. Method: First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, shaking vigorously after each aliquot of water.		
50 mL	100 mg per 5 mL	Suspend in a total of 30 mL of distilled water. Method: First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, shaking vigorously after each aliquot of water.		
75 mL	100 mg per 5 mL	Suspend in a total of 43 mL of distilled water. Method: First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, shaking		

		vigorously after each aliquot of water.
100 mL	100 mg per 5 mL	Suspend in a total of 57 mL of distilled water. Method:
		First, shake the bottle to loosen granules. Then add the
	water in two approximately equal portions, shaking	
		vigorously after each aliquot of water.

After mixing, the suspension should be stored in a refrigerator, 2° to 8°C (36° to 46°F). Shake well before using. Keep container tightly closed. The mixture may be used for 14 days. Discard unused portion after 14 days.

HOW SUPPLIED

Cefpodoxime Proxetil for Oral Suspension, USP provides the equivalent of 50 mg or 100 mg cefpodoxime per 5 mL suspension (when constituted as directed) and is available as off-white colored granular powder in the following sizes:

50 mg/5 mL

50-mL suspension	NDC 65862-140-50
75-mL suspension	NDC 65862-140-75
100-mL suspension	NDC 65862-140-01

100 mg/5 mL

50-mL suspension	NDC 65862-141-50
75-mL suspension	NDC 65862-141-75
100-mL suspension	NDC 65862-141-01

Store unsuspended granules at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Directions for mixing are included on the label. After mixing, suspension should be stored in a refrigerator, 2° to 8°C (36° to 46°F). Shake well before using. Keep container tightly closed. The mixture may be used for 14 days. Discard unused portion after 14 days.

CLINICAL TRIALS

Cystitis

In two double-blind, 2:1 randomized, comparative trials performed in adults in the United States, cefpodoxime proxetil was compared to other beta-lactam antibiotics. In these studies, the following bacterial eradication rates were obtained at 5 to 9 days after therapy:

Pathogen	Cefpodoxime	Comparator
E. coli	200/243 (82%)	99/123 (80%)
Other pathogens	34/42 (81%)	23/28 (82%)
K. pneumoniae		
P. mirabilis		
S. saprophyticus		
TOTAL	234/285 (82%)	122/151 (81%)

In these studies, clinical cure rates and bacterial eradication rates for cefpodoxime proxetil were comparable to the comparator agents; however, the clinical cure rates and bacteriologic eradication

rates were lower than those observed with some other classes of approved agents for cystitis.

Acute Otitis Media Studies

In controlled studies of acute otitis media performed in the United States, where significant rates of beta-lactamase-producing organisms were found, cefpodoxime proxetil was compared to cefixime. In these studies, using very strict evaluability criteria and microbiologic and clinical response criteria at the 4 to 21 day post-therapy follow-up, the following presumptive bacterial eradication/clinical success outcomes (cured and improved) were obtained.

	Cefpodoxime Proxetil	Cefixime
Pathogen	5 mg/kg Q 12 h x 5 d	
S. pneumoniae	88/122 (72%)	72/124 (58%)
H. influenzae	50/76 (66%)	61/81 (75%)
M. catarrhalis	22/39 (56%)	23/41 (56%)
S. pyogenes	20/25 (80%)	13/23 (57%)
Clinical success rate	171/254 (67%)	165/258 (64%)

Distributed by: **Aurobindo Pharma USA, Inc.** 279 Princeton-Hightstown Road East Windsor, NJ 08520

Manufactured by: **Aurobindo Pharma Limited** Hyderabad-500 038, India

Revised: 10/2018

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg/5 mL (100 mL Bottle)

NDC 65862-140-01 Rx only Cefpodoxime Proxetil for Oral Suspension, USP 50 mg/5 mL* 100 mL when constituted AUROBINDO

NDC 65862-140-01	*Each 5 mL of suspension contains cefpodoxime proxetil USP equivalent to 50 mg cefpodoxime.	Shake well before using. Keep container tightly closed. The mixture may be
NDC 65662-140-01	Usual Dosage: See package insert for Dosage and Administration.	used for 14 days. Discard o
	Warning: Not for injection.	Distributed by:
Rx only	Store unconstituted granules at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room	Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520
	Temperature]. Store constituted suspension in a refrigerator 2° to 8°C (36° to 46°F).	Made in India
Cefpodoxime Proxetil for Oral Suspension, USP	Directions for use: Before reconstitution, remove the desiccant capsule by pulling out two small rings, then discard.	Code: TS/DRUGS/78/1996
50 mg/5 mL*	Directions for mixing. Shake bottle to loosen	P1422180
	granules. Add approximately 1/2 the total amount of distilled water required for constitution (total water = 57 mL). Shake vigorously to wet the granules. Add remaining water and shake vigorously.	*
AUROBINDO 100 mL when constituted	Keep this and all drugs out of the reach of children.	
		L
		*Over Printing Zone

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg/5 mL Carton Label

NDC 65862-140-01 Cefpodoxime Proxetil for Oral Suspension, USP 50 mg/5 mL* Rx only 100 mL when constituted AUROBINDO



PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/5 mL (100 mL Bottle)

NDC 65862-141-01 Rx only Cefpodoxime Proxetil for Oral Suspension, USP 100 mg/5 mL* 100 mL when constituted

AUROBINDO

	*Each 5 mL of suspension contains cefpodoxime		
NDC 65862-141-0	provetil LISP equivalent to 100 mg cefpodovime	Shake well before using. Keep container tightly closed. The	N 3 6
NDC 65862-141-0	Usual Dosage: See package insert for Dosage and Administration.	mixture may be used for 14 days. Discard unused portion after 14 days.	586
	Warning: Not for injection.	Distributed by:	2
Rx only	Store unconstituted granules at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room	Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520	4101
	Temperature]. Store constituted suspension in a refrigerator 2° to 8°C (36° to 46°F).	Made in India	9
Cefpodoxime Proxetil for Oral Suspension, USP	Directions for use: Before reconstitution, remove the desiccant capsule by pulling out two small rings, then discard.	Code: TS/DRUGS/78/1996	
100 mg/5 mL*	Directions for mixing. Shake bottle to loosen granules. Add approximately 1/2 the total amount of distilled water required for constitution (total water = 57 mL). Shake vigorously to wet the granules. Add remaining water and shake vigorously.	P1422183	
AUROBINDO 100 mL when constituted	Keep this and all drugs out of the reach of children.		

*Over Printing Zone

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Carton Label

NDC 65862-141-01 Cefpodoxime Proxetil for Oral Suspension, USP 100 mg/5 mL* Rx only 100 mL when constituted AUROBINDO



CEFPODOXIME PROXETIL				
cefpodoxime proxetil granule, for suspension				
Product Information				
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:65862-140	
Route of Administration	ORAL			

	ive Ingredien	t/Active Moiety					
		Basis of Str	ength	Stren	gth		
CEF	PO DO XIME PRO	CEFPODOXIM	E	50 mg in	5 m		
Ina	ctive Ingredie	ents					
		Ingredient Name				Stren	gtl
LAC	TOSE MONOHY	DRATE (UNII: EWQ57Q8I5X)					0
STA	RCH, CORN (UNI	I: O8232NY3SJ)					
CRO	SCARMELLOSE	SODIUM (UNII: M28OL1HH48)					
FER	RIC O XIDE YELI	.OW (UNII: EX438O2MRT)					
HYD	ROXYPROPYL	CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)					
MIC	ROCRYSTALLIN	E CELLULOSE (UNII: OP1R32D61U)					
CAR	BOXYMETHYLC	ELLULOSE SODIUM, UNSPECIFIED FORM (UNII: K679	90BS311)				
SILI	CON DIO XIDE (U	JNII: ETJ7Z6XBU4)					
ANH	IYDROUS CITRIC	C ACID (UNII: XF417D3PSL)					
TRIS	SO DIUM CITRAT	E DIHYDRATE (UNII: B22547B95K)					
SOD	DIUM BENZOATE	(UNII: OJ245FE5EU)					
SUC	ROSE (UNII: C151	H8 M554)					
	duct Charact	eristics		-			
Pro Colo Shaj	Dr	eristics		Score Size			
Colo Shaj	or pe	e ristics LEMON (Citron) , VANILLA (Vanille)			le		
Colo Shaj Flav	or pe			Size	le		
Colo Shaj Flav	or pe /or			Size	le		
Colo Shaj Flav Con	or pe /or			Size	le		
Colo Shaj Flav Con Pac	or pe /or tains		Marketing	Size		ting End	Da
Colo Shaj Flav Con Pac #	or pe or tains ckaging	LEMON (Citron) , VANILLA (Vanille) Package Description	Marketing 06/08/2007	Size Imprint Cod		ting End	Da
Cold Shaj Flav Con Pac #	or pe /or 2 tains ckaging Item Code	LEMON (Citron) , VANILLA (Vanille) Package Description	-	Size Imprint Cod		ting End	Da
Cold Shaj Flav Con Pac # 1 Ni 1	or pe /or 2 tains ckaging Item Code	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product	-	Size Imprint Cod		ting End	Da
Cold Shaj Flav Con Pac # 1 Ni 1	or pe /or tains ckaging Item Code DC:65862-140-50	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007	Size Imprint Cod		ting End	Da
Cold Sha Flav Con Pac # 1 N1 1 N1 1 N1 2 N1 2 N1	or pe /or tains ckaging Item Code DC:65862-140-50	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007	Size Imprint Cod		ting End	Da
Cold Sha Flav Con # 1 N1 1 2 N1 2 N1 2	or pe for tains tains Ckaging Item Code DC:65862-140-50	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007 06/08/2007 06/08/2007	Size Imprint Cod		ting End	Da
Cold Shaj Flav Con	or pe for tains tains Ckaging Item Code DC:65862-140-50	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON	06/08/2007 06/08/2007 06/08/2007	Size Imprint Cod		ting End	Da
Cold Sha Flav Con # 1 N1 1 N1 2 N1 2 N1 3 N1 3	or pe /or tains :kaging Item Code DC:65862-140-50 DC:65862-140-01	Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 70 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 100 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007 06/08/2007 06/08/2007	Size Imprint Cod		ting End	Da
Cold Shaj Flav Con # 1 N1 2 N1 2 N1 3 N1 3 N1 3 N1	or pe for tains tains ckaging Item Code DC:65862-140-50 DC:65862-140-75 DC:65862-140-01	Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 100 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 20 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 20 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 20 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007 06/08/2007 06/08/2007	Size Imprint Cod	Marke		
Cold Sha Flav Con # 1 N1 1 2 N1 2 N1 2 N1 3 N1 3 N1 3 N1 3	or pe vor tains tains tains tains tains tains tains tains tains tains tem Code DC:65862-140-50 DC:65862-140-75 DC:65862-140-01	Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 100 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 20 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 20 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 20 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007 06/08/2007 06/08/2007	Size Imprint Cod	Marke	ting End	

CEFPODOXIME PROXETIL

cefpodoxime proxetil granule, for suspension

Product Information					
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:65862-141		
Route of Administration	ORAL				

	t/Active Moiety			
	I	Basis of Strength	Strength	
CEFPO DO XIME PRO	EFPODOXIME	100 mg in 5 ml		
Inactive Ingredi	ents			
	Ingredient Name			Strength
LACTOSE MONOHY	DRATE (UNII: EWQ57Q8I5X)			
STARCH, CORN (UN	I: O8232NY3SJ)			
CROSCARMELLOSE	SODIUM (UNII: M28OL1HH48)			
FERRIC OXIDE YELI	LOW (UNII: EX438O2MRT)			
HYDRO XYPRO PYL	CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)			
MICROCRYSTALLIN	E CELLULOSE (UNII: OP1R32D61U)			
CARBOXYMETHYLO	CELLULOSE SODIUM, UNSPECIFIED FORM (UNII: K679	OBS311)		
SILICON DIO XIDE (U	JNII: ETJ7Z6XBU4)			
ANHYDROUS CITRIC	C ACID (UNII: XF417D3PSL)			
TRISO DIUM CITRAT	E DIHYDRATE (UNII: B22547B95K)			
SODIUM BENZOATE	E (UNII: OJ245FE5EU)			
SUCROSE (UNII: C15	H8 M554)			
Due duet Chauset	aviation			
Product Charact	eristics		Score	
Color Shape			Size	
Color Shape Flavor	e ristics LEMON (Citron) , VANILLA (Vanille)			
Color Shape			Size	
Color Shape Flavor Contains			Size	
Color Shape Flavor Contains Packaging	LEMON (Citron) , VANILLA (Vanille)		Size Imprint Code	
Color Shape Flavor Contains Packaging # Item Code	LEMON (Citron) , VANILLA (Vanille) Package Description	Ū	Size	eting End Dat
Color Shape Flavor Contains Exclaging # Item Code 1 NDC:65862-141-50	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON	Marketing 06/08/2007	Size Imprint Code	eting End Dat
Color Shape Flavor Contains Packaging I tem Code NDC:65862-141-50	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007	Size Imprint Code	eting End Dat
Color Shape Flavor Contains Packaging MC:65862-141-50 1 NDC:65862-141-75	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON	Ū	Size Imprint Code	eting End Dat
Color Shape Flavor Contains	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007	Size Imprint Code	eting End Dat
Color Shape Flavor Contains	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON	06/08/2007	Size Imprint Code	eting End Dat
Color Shape Flavor Contains Con	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007	Size Imprint Code	eting End Dat
Color Shape Flavor Contains Con	LEMON (Citron) , VANILLA (Vanille) Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON	06/08/2007	Size Imprint Code	eting End Dat
Color Shape Shape Flavor Contains	Package Description 1 in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 100 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007	Size Imprint Code	eting End Dat
Color Shape Flavor Contains Packaging	Package Description I in 1 CARTON 50 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 75 mL in 1 BOTTLE; Type 0: Not a Combination Product 1 in 1 CARTON 100 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/08/2007	Size Imprint Code Start Date Mark	eting End Dat

Labeler - Aurobindo Pharma Limited (650082092)

Establishment				
Name	Address	ID/FEI	Business Operations	
Aurobindo Pharma Limited		9 18 9 17 6 3 9	ANALYSIS(65862-140, 65862-141), MANUFACTURE(65862-140, 65862-141)	